Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Verastem, Inc.

NASDAQ: VSTM · Life Sciences · 7 alerts · CIK 1526119

Share price
$7.70Close, Nov 16
Market cap
$970M
Shares outstanding
126.01MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Verastem, Inc. filings on SEC EDGAR ↗

7:53 PM ET Form 4
Insider Selling

Verastem President and CEO Dan Paterson Sells $12.5K of Stock

Dan Paterson, President and CEO, sold 1,299 shares of Verastem, Inc. at $9.60 a share, worth $12.5K in total on Nov 3, 2026. Shares held after the trade: 651,413 (-0.2%).

Value
$12.5K
Shares
1,299
Price
$9.60
Role
President and CEO
Holding change
-0.2%
Trade date
Nov 3, 2026
4:33 PM ET 8-K
Investor Presentation

Verastem Investor Presentation

Verastem Oncology (VSTM) has published an updated corporate presentation for November 2026 detailing its pipeline of RAS/MAPK pathway-driven cancer therapies. The presentation highlights the commercialization strategy for AVMAPKI FAKZYNJA CO-PACK in recurrent low-grade serous ovarian cancer (LGSOC) and provides updates on its clinical trial programs, including RAMP 301 and collaborations with GenFleet Therapeutics.

4:03 PM ET 10-Q
Financial Results

Verastem Q3 2026 Results: Net Loss of $74.7M, Loss Narrows

Verastem reported Q3 2026 net product revenue of $24.0 million, a significant increase from $11.2 million in the prior year, driven by AVMAPKI FAKZYNJA CO-PACK sales. Despite a GAAP net loss of $74.7 million, the company strengthened its balance sheet with a $250 million follow-on offering in October, extending its cash runway into the first half of 2028.

Key figure
Net loss $74.7M
5:21 PM ET 8-K
Capital Raise

Verastem Capital Raise of $235M

Verastem, Inc. entered into an underwriting agreement for a public offering of 30,937,500 shares of common stock and pre-funded warrants to purchase 312,503 shares. The common stock is priced at $8.00 per share, with the company expecting to receive net proceeds of approximately $234.7 million. The offering is expected to close on or about October 15, 2026.

Value
$235M
Counterparty
Jefferies LLC and Guggenheim Securities, LLC
6:08 AM ET 8-K
Leadership Change

Verastem Leadership Change

Verastem Oncology announced that Daniel W. Paterson will retire as President and CEO effective January 1, 2027, and will be succeeded by Michael P. Bailey. Mr. Paterson will remain on the Board of Directors and serve as an advisor, while Mr. Bailey, an existing director with over 30 years of industry experience, will lead the company's next phase of commercial growth.

5:16 PM ET Form 4
Insider Selling

Verastem President and CEO Dan Paterson Sells $353K of Stock

Dan Paterson, President and CEO, sold 44,121 shares of Verastem, Inc. at $8.00 a share, worth $353K in total on Oct 1, 2026. Shares held after the trade: 652,712 (-6.3%).

Value
$353K
Shares
44,121
Price
$8.00
Role
President and CEO
Holding change
-6.3%
Trade date
Oct 1, 2026
5:15 PM ET Form 4
Insider Selling

Verastem CFO Daniel Calkins Sells $20.5K of Stock

Daniel Calkins, CFO, sold 2,566 shares of Verastem, Inc. at $8.00 a share, worth $20.5K in total on Oct 1, 2026. Shares held after the trade: 123,781 (-2.0%).

Value
$20.5K
Shares
2,566
Price
$8.00
Role
CFO
Holding change
-2.0%
Trade date
Oct 1, 2026

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.